Novo Nordisk risks insulin shock on Chinese market

Novo Nordisk risks taking a hard blow on the lucrative Chinese market, which is the firm's second-largest. Novo Nordisk executive recognizes the potential challenge.

Photo: Novo Nordisk Pharmatech/PR

Dark clouds are gathering over Novo Nordisk's lucrative Chinese market.

In the worst-case scenario, a new tender model might shave billions of kroner off the DKK 20bn (USD 3.3bn) Chinese market for insulin treatment.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs